Clonidine is NOT recommended as a primary treatment for anxiety disorders
Clonidine should not be used as a first-line or routine treatment for anxiety, as it lacks FDA approval for this indication, has inconsistent efficacy data, and carries significant cardiovascular risks including hypotension, bradycardia, and rebound hypertension upon discontinuation 1.
Evidence Quality and Regulatory Status
The evidence base for clonidine in anxiety is weak and outdated. The FDA has approved clonidine only for hypertension and ADHD (extended-release formulations), not for anxiety disorders 2, 1. The most recent guideline evidence (2026) examining treatment-resistant anxiety disorders lists clonazepam and other agents for social anxiety disorder, but notably does not recommend clonidine as a standard option 3.
Research Evidence Shows Mixed and Limited Results
The available research is predominantly from the 1980s-1990s with small sample sizes and conflicting outcomes:
- A 1981 study showed clonidine was superior to placebo in some patients, but 17% of patients worsened on the medication 4
- A 1989 study found short-term anxiolytic effects that did not persist with long-term administration in most patients 5
- A 1992 study showed clonidine blocked lactate-induced panic in only 4 of 10 subjects, with over half still experiencing panic despite treatment 6
The most recent 2025 review acknowledges clonidine's "potential" but emphasizes the lack of large-scale validation and notes inconsistencies in efficacy 7.
Significant Safety Concerns
Clonidine carries substantial risks that make it unsuitable for routine anxiety treatment:
- Cardiovascular effects: Hypotension, bradycardia, syncope, and cardiac conduction abnormalities 2
- Dangerous withdrawal syndrome: Sudden discontinuation causes rebound hypertension and tachycardia; the 2025 hypertension guidelines specifically recommend avoiding clonidine when possible due to withdrawal risks 8
- CNS depression: Somnolence, sedation, and fatigue are common, worsened by alcohol or other sedating drugs 2, 1
- Conduction abnormalities: Post-marketing reports document severe bradycardia requiring IV atropine and temporary pacing, especially with other sympatholytic drugs 1
Limited Clinical Context Where Clonidine Might Be Considered
The only scenario where clonidine has reasonable evidence is PTSD-associated nightmares, where it received a Level C recommendation (may be considered) in 2010 guidelines, though prazosin was preferred (Level A) 9. Even here, the evidence consists of only two small case series from a single site.
For general anxiety disorders, panic disorder, or social anxiety disorder, clonidine lacks the evidence base, regulatory approval, and safety profile to justify its use when effective alternatives exist (SSRIs, SNRIs, buspirone, pregabalin, or CBT).
Clinical Bottom Line
Use evidence-based first-line treatments for anxiety: SSRIs (escitalopram, sertraline, paroxetine), SNRIs (venlafaxine, duloxetine), buspirone, or pregabalin combined with cognitive-behavioral therapy. Reserve clonidine only for the narrow indication of PTSD-related nightmares when prazosin is unavailable or contraindicated, and only after discussing the cardiovascular risks and need for gradual tapering if discontinuation becomes necessary 9, 3.